April 9, 2024 10:58 AM EDT
News Briefing

Acrivon draws in $130M; Vin­cerx Phar­ma's Ph1 metasta­t­ic tu­mor da­ta

ENDPOINTS

Acrivon rais­es $130M PIPE: The pre­ci­sion on­col­o­gy biotech brought in the mon­ey from RA Cap­i­tal, Per­cep­tive Ad­vi­sors and oth­er in­vestors. Its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Is there room for MASH drugs in a GLP-1 world?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times